항정신병약물의 생물학적 기전 최신 지견

참고문헌 (63)

1. Carlsson A, "Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain", Acta Pharmacol Toxicol(Copenh), 20, pp.140~144 (1963)
2. Davis KL, "Dopamine in schizophrenia : a review and reconceptualization", Am J Psychiatry, 148, pp.1474~1486 (1991)
3. Pickar D, "Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients", Science, 225, pp.954~957 (1984)
4. Creese I, "Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs", J Neuropsychiatry Clin Neurosci, 8, pp.223~226 (1996)
5. Davis JM, "A meta-analysis of the efficacy of second-generation antipsychotics", Arch Gen Psychiatry, 60, pp.553~564 (2003)
6. Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis", Lancet, 382, pp.951~962 (2013)
7. Crilly J, "The history of clozapine and its emergence in the US market : a review and analysis", Hist Psychiatry, 18, pp.39~60 (2007)
8. Hippius H, "A historical perspective of clozapine", J Clin Psychiatry, 60(Suppl 12), pp.22~23 (1999)
9. Nucifora FC Jr, "Clozapine as a model for antipsychotic development", Neurotherapeutics, 14, pp.750~761 (2017)
10. Amato D, "Serotonin in antipsychotic drugs action", Behav Brain Res, 277, pp.125~135 (2015)
11. Meltzer HY, "Serotonergic mechanisms as targets for existing and novel antipsychotics", Handb Exp Pharmacol, pp.87~124 (2012)
12. Forray C, "Challenges and opportunities for the development of new antipsychotic drugs", Biochem Pharmacol, 143, pp.10~24 (2017)
13. Kondej M, "Multi-target approach for drug discovery against schizophrenia", Int J Mol Sci, 19, pp.E3105~ (2018)
14. Molteni R, "Antipsychotic drug actions on gene modulation and signaling mechanisms", Pharmacol Ther, 124, pp.74~85 (2009)
15. Bateup HS, "Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs", Nat Neurosci, 11, pp.932~939 (2008)
16. Fienberg AA, "DARPP-32 : regulator of the efficacy of dopaminergic neurotransmission", Science, 281, pp.838~842 (1998)
17. Wang H, "The involvement of DARPP-32 in the pathophysiology of schizophrenia", Oncotarget, 8, pp.53791~53803 (2017)
18. Masri B, "Antagonism of dopamine D2 receptor", beta-arrestin 2interaction is a common property of clinically effective antipsychotics, 2008, pp.105, 13656~13661
19. Urs NM, "Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties", Proc Natl Acad Sci U S A, 113, pp.E8178~E8186 (2016)
20. Halene TB, "Antipsychotic-like properties of phosphodiesterase 4 inhibitors: evaluation of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with auditory event-related potentials and prepulse inhibition of startle", J Pharmacol Exp Ther, 326, pp.230~239 (2008)
21. Lipina TV, "Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL", 6J mice, 2013, pp.64, 205~214
22. Pandey MK, "Glycogen synthase kinase-3(GSK-3)-targeted therapy and imaging", Theranostics, 6, pp.571~593 (2016)
23. Wiescholleck V, "PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis", Transl Psychiatry, 2, pp.e89~ (2012)
24. Hanson ND, "Depression, antidepressants, and neurogenesis : a critical reappraisal", Neuropsychopharmacology, 36, pp.2589~2602 (2011)
25. Kusumi I, "Psychopharmacology of atypical antipsychotic drugs : from the receptor binding profile to neuroprotection and neurogenesis", Psychiatry Clin Neurosci, 69, pp.243~258 (2015)
26. Nandra KS, "The differences between typical and atypical antipsychotics: the effects on neurogenesis", Psychiatr Danub, 24(Suppl 1), pp.S95~S99 (2012)
27. Gassó P, "Neurotoxic", neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells, 2012, pp.36, 71~77
28. Dakir EH, "The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer", Oncotarget, 9, pp.34889~34910 (2018)
29. Md. Saiful Islam Roney, "Antipsychotic dopamine receptor antagonists, cancer, and cancer stem cells", Archives of Pharmacal Research, 41(4), pp.384~408 (2018), 대한약학회
30. Wu CH, "Pharmacological exploitation of the phenothiazine antipsychotics to develop novel antitumor agents-a drug repurposing strategy", Sci Rep, 6, pp.27540~ (2016)
31. Zhang W, "Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases", Sci Rep, 8, pp.15753~ (2018)
32. Sachlos E, "Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells", Cell, 149, pp.1284~1297 (2012)
33. Frade JM, "Neuronal cell cycle : the neuron itself and its circumstances", Cell Cycle, 14, pp.712~720 (2015)
34. Nixon RA, "The role of autophagy in neurodegenerative disease", Nat Med, 19, pp.983~997 (2013)
35. Merenlender-Wagner A, "Autophagy has a key role in the pathophysiology of schizophrenia", Mol Psychiatry, 20, pp.126~132 (2015)
36. Merenlender-Wagner A, "New horizons in schizophrenia treatment : autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia", Autophagy, 10, pp.2324~2332 (2014)
37. Schneider JL, "Autophagy and schizophrenia : a closer look at how dysregulation of neuronal cell homeostasis influences the pathogenesis of schizophrenia", Einstein J Biol Med, 31, pp.34~39 (2016)
38. Ranjan A, "Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis", Sci Rep, 6, pp.26165~ (2016)
39. Shin SY, "The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt", mTOR pathway in human U-87MG glioma cells, 2013, pp.34, 2080~2089
40. Yin YC, "Clozapine induces autophagic cell death in non-small cell lung cancer cells", Cell Physiol Biochem, 35, pp.945~956 (2015)
41. Kim SH, "The antipsychotic agent clozapine induces autophagy via the AMPK-ULK1-Beclin1signaling pathway in the rat frontal cortex", Prog Neuropsychopharmacol Biol Psychiatry, 81, pp.96~104 (2018)
42. Choi Y, "Clozapine improves memory impairment and reduces Aβ level in the Tg-AP Pswe", PS1dE9 mouse model of Alzheimer’s disease, 2017, pp.54, 450~460
43. Tourjman V, "Antipsychotics’ effects on blood levels of cytokines in schizophrenia : a meta-analysis", Schizophr Res, 151, pp.43~47 (2013)
44. Müller N, "Anti-inflammatory treatment in schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 42, pp.146~153 (2013)
45. Jeon S, "Clozapine reduces Toll-like receptor 4", NF-κB-mediated inflammatory responses through inhibition of calcium, Prog Neuropsychopharmacol Biol Psychiatry, pp.2018, 81[DOI]
46. Dandona P, "Inflammation : the link between insulin resistance, obesity and diabetes", Trends Immunol, 25, pp.4~7 (2004)
47. Fonseka TM, "Inflammatory cytokines and antipsychotic-induced weight gain : review and clinical implications", Mol Neuropsychiatry, 2, pp.1~14 (2016)
48. Cui D, "Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy", J Clin Invest, 128, pp.4997~5007 (2018)
49. Kim SF, "From the cover : antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase", Proc Natl Acad Sci U S A, 104, pp.3456~3459 (2007)
50. Kim MK, "The effect of clozapine on the AMPK-ACC-CPT1 pathway in the rat frontal cortex", Int J Neuropsychopharmacol, 15, pp.907~917 (2012)
51. Girgis RR, "Antipsychotic drug mechanisms : links between therapeutic effects, metabolic side effects and the insulin signaling pathway", Mol Psychiatry, 13, pp.918~929 (2008)
52. Guidotti A, "Characterization of the action of antipsychotic subtypes on valproateinduced chromatin remodeling", Trends Pharmacol Sci, 30, pp.55~60 (2009)
53. Hyman SE, "Target practice : HDAC inhibitors for schizophrenia", Nat Neurosci, 15, pp.1180~1181 (2012)
54. Kurita M, "HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity", Nat Neurosci, 15, pp.1245~1254 (2012)
55. De la Fuente Revenga M, "HDAC2-dependent antipsychotic-like effects of chronic treatment with the HDAC Inhibitor SAHA in mice", Neuroscience, 388, pp.102~117 (2018)
56. Ibi D, "Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects", Nat Neurosci, 20, pp.1247~1259 (2017)
57. Swathy B, "Understanding epigenetics of schizophrenia in the backdrop of its antipsychotic drug therapy", Epigenomics, 9, pp.721~736 (2017)
58. Dong E, "Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation", Epigenomics, 1, pp.201~211 (2009)
59. Dong E, "Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation", Proc Natl Acad Sci U S A, 105, pp.13614~13619 (2008)
60. Guidotti A, "DNA methylation and demethylation as targets for antipsychotic therapy", Dialogues Clin Neurosci, 16, pp.419~429 (2014)
61. Kim SH, "Haloperidol induces demethylation and expression of the dual specificity phosphatase 6gene in MIA PaCa-2 human pancreatic cancer cells", Life Sci, 91, pp.1317~1322 (2012)
62. Luoni A, "MicroRNAs and psychiatric disorders : from aetiology to treatment", Pharmacol Ther, 167, pp.13~27 (2016)
63. Swathy B, "Pharmacoepigenomic responses of antipsychotic drugs on pharmacogenes are likely to be modulated by miRNAs", Epigenomics, 9, pp.811~821 (2017)

관련 논문AI추천